Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes
HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”)…
News
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has…
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline’s anti-IL-6 antibody (TOUR006)…
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical…
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
Proceeds to Be Used to Redeem All of the Outstanding 5.75% Convertible Unsecured Senior Notes…
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter…
Avicanna Sponsors New Medical Cannabis Education and Training Campaign in Canada with the Canadian Consortium for the Investigation of Cannabinoids (“CCIC”)
Through a sponsorship agreement CCIC’s accredited Canadian Cannabis Syllabus will be made available to the…
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
ASLAN will receive up to $15 million in upfront and near-term payments and up to…
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
This is the first-ever long-duration data reported for an anti-TL1A antibody At the expected Phase…
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the safety and efficacy of…
Montauk Brewing Company Celebrates 11-Year Anniversary and Announces 2023 Summer Season Lineup
New York’s Leading Craft Brewer Introduces New Summer Beers and Expands Brew Barn Bar Locations…
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
WESTLAKE VILLAGE, Calif., June 22, 2023 (GLOBE NEWSWIRE) — Genelux Corporation (NASDAQ: GNLX), a late…
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported…
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3…
TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology…
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024…
Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas’
Media Release COPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that…
Bright Minds Announces Proposed Share Consolidation
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG)…
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the…
Progress Helps Organizations Unlock the Full Potential of IT Infrastructure Management with WhatsUp Gold
Latest release of Progress WhatsUp Gold provides organizations with advanced configuration management, configurable NOC views…